Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer

NCT03316222 is registered in ClinicalTrials.gov with Genoscience Pharma as lead sponsor.

NCT NCT03316222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03316222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer
Lead sponsor
Genoscience Pharma
Phase
Phase 1/2
Overall status
Terminated
Start date
April 4, 2018
Completion date
April 25, 2022
Enrollment
50 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, intrahepatic, hepatocellular carcinoma